What is the price-to-earnings ratio of SI-BONE?
The price-earnings ratio of SI-BONE is currently -16.31.
SI-BONE P/E 2024
SI-BONE P/E
-16.31
Ticker
SIBN
ISIN
US8257041090
WKN
A2N7LY
As of Dec 12, 2024, SI-BONE's P/E ratio was -16.31, a -27.09% change from the -22.37 P/E ratio recorded in the previous year.
The SI-BONE P/E history
SI-BONE Aktienanalyse
What does SI-BONE do?
SI-BONE Inc. is an innovative medical technology company based in Santa Clara, California. It was founded in 2008 by a group of orthopedic surgeons, engineers, and entrepreneurs who aimed to improve the treatment of lower back pain. The company is now globally recognized and specializes in the development and marketing of implants for the treatment of pain and discomfort in the pelvic and back areas. SI-BONE focuses on the treatment of pain and discomfort in the pelvic and back areas, offering a range of products for this purpose. The company's main focus is on the development of innovative implants that can be used minimally invasively, with the goal of providing patients with quick recovery and improved quality of life. The flagship product of SI-BONE is the iFuse implant. This implant is used in patients with chronic lower back pain caused by instability of the spine or pelvis. The iFuse implant stabilizes the pelvis and thereby reduces the pain originating from the unstable joint region. The iFuse implant has been FDA approved and is now available in over 40 countries worldwide. In addition to the iFuse implant, SI-BONE also offers a variety of other products tailored to the needs of physicians and patients. These include implantable instruments and consumables such as bone screws or arthroscopy needles. SI-BONE is a publicly traded company listed on NASDAQ under the ticker symbol "SIBN." The company's business model is based on providing innovative products to physicians and hospitals that optimize the treatment of back pain. To achieve this, SI-BONE works closely with leading industry professionals to enable optimal treatment of back pain. SI-BONE has established itself as a strong, innovative company specializing in minimally invasive implants in the field of pain therapy. Through close collaboration with physicians and specialists and investment in research and development of cutting-edge technologies, SI-BONE aims to continue growing and achieve a leading position in the field of pain therapy. SI-BONE ist eines der beliebtesten Unternehmen auf Eulerpool.com.P/E Details
Deciphering SI-BONE's P/E Ratio
The Price to Earnings (P/E) Ratio of SI-BONE is a vital metric that investors and analysts use to determine the company’s market value relative to its earnings. It is calculated by dividing the current stock price by the earnings per share (EPS). A higher P/E ratio could suggest that investors are expecting higher future growth, while a lower ratio may indicate a potentially undervalued company or lower growth expectations.
Year-to-Year Comparison
Assessing SI-BONE's P/E ratio on a yearly basis provides insights into the valuation trends and investor sentiment. An increasing P/E ratio over the years signifies growing investor confidence and expectations for future earnings growth, while a decreasing ratio may reflect concerns over the company's profitability or growth prospects.
Impact on Investments
The P/E ratio of SI-BONE is a key consideration for investors aiming to balance risk and reward. A comprehensive analysis of this ratio, in conjunction with other financial indicators, aids investors in making informed decisions regarding buying, holding, or selling the company’s stocks.
Interpreting P/E Ratio Fluctuations
Fluctuations in SI-BONE’s P/E ratio can be attributed to various factors including changes in earnings, stock price movements, and shifts in investor expectations. Understanding the underlying reasons for these fluctuations is essential for predicting future stock performance and assessing the company's intrinsic value.
Frequently Asked Questions about SI-BONE stock
How has the price-earnings ratio of SI-BONE changed compared to last year?
The price-to-earnings ratio of SI-BONE has increased by -27.09% fallen (meaning "decreased" or "dropped") compared to last year.
What consequences does a high price-earnings ratio have for investors?
A high price-to-earnings ratio indicates that the company's stock is relatively expensive and investors may potentially achieve a lower return.
What does a low price-earnings ratio mean?
A low price-earnings ratio means that the company's stock is relatively cheap and investors may potentially achieve a higher return.
Is the price-earnings ratio of SI-BONE high compared to other companies?
Yes, the price-to-earnings ratio of SI-BONE is high compared to other companies.
How does an increase in the price-earnings ratio of SI-BONE affect the company?
An increase in the price-earnings ratio of SI-BONE would lead to a higher market capitalization of the company, which in turn would lead to a higher valuation of the company.
How does a reduction in the price-to-earnings ratio of SI-BONE affect the company?
A decrease in the price-earnings ratio of SI-BONE would result in a lower market capitalization of the company, which in turn would lead to a lower valuation of the company.
What are some factors that influence the price-earnings ratio of SI-BONE?
Some factors that influence the price-earnings ratio of SI-BONE are the company's growth, financial position, industry development, and the overall economic situation.
How much dividend does SI-BONE pay?
Over the past 12 months, SI-BONE paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, SI-BONE is expected to pay a dividend of 0 USD.
What is the dividend yield of SI-BONE?
The current dividend yield of SI-BONE is .
When does SI-BONE pay dividends?
SI-BONE pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of SI-BONE?
SI-BONE paid dividends every year for the past 0 years.
What is the dividend of SI-BONE?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is SI-BONE located?
SI-BONE is assigned to the 'Health' sector.
Wann musste ich die Aktien von SI-BONE kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of SI-BONE from 12/12/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 12/12/2024.
When did SI-BONE pay the last dividend?
The last dividend was paid out on 12/12/2024.
What was the dividend of SI-BONE in the year 2023?
In the year 2023, SI-BONE distributed 0 USD as dividends.
In which currency does SI-BONE pay out the dividend?
The dividends of SI-BONE are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
The SI-BONE stock can be added to a savings plan with the following providers: Trade Republic
Andere Kennzahlen von SI-BONE
Our stock analysis for SI-BONE Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of SI-BONE Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
